TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22784349
Drug: Manasamitra Vataka
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manasamitra Vataka tablets (100 mg twice daily for 30 days) + Shirodhara (first 7 days)
Study: 22784349
Drug: Clonazepam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 0.75 mg daily in divided dose for 30 days
Study: 20409337
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream for 6 weeks (superficial basal cell carcinoma) or 12 weeks (nodular basal cell carcinoma)
Study: 16086364
Drug: Hydroxyzine HCl
Normalized name: hydroxyzine HCl
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine HCl 30 mg
Study: 12697867
Drug: High-dose chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days (HD-CHL-P; arm A)
Study: 12697867
Drug: High-dose chlorambucil
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose chlorambucil (15 mg/m2/d) plus prednisone (100 mg/d) for 5 days plus epirubicin 60 mg/m2 intravenous on day 1 (arm B)
Study: 12697867
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFNalpha-2a; 3 MU, three times weekly) for 12 months
Study: 10933079
Drug: Children seen
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children seen by treatment group physicians.
Study: 8879895
Drug: IFN‐alpha daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha daily for 4 weeks and then intermittently for 20 weeks (total dose, 348 MU)
Study: 8879895
Drug: IFN‐alpha daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha daily for 2 weeks and then intermittently for 22 weeks (total dose, 480 MU)
Study: 8879895
Drug: IFN‐alpha daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha daily for 8 weeks (total dose, 336 MU)
Study: 30768414
Drug: Combined cognitive‐behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined cognitive‐behavioral and fluoxetine treatment (COMB)
Study: 28356125
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy offered three times per week in a community centre with a focus on songwriting.
Study: 27693439
Drug: Chlorhexidine umbilical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine umbilical cord care (10 mL of a 4% chlorhexidine solution applied once per day until 3 days after cord drop)
Study: 24118830
Drug: Fluvastatin (Lescol®)
Normalized name: fluvastatin Oral Capsule [Lescol]
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (Lescol®) 40-80 mg
Study: 24118830
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (Omacor®) high-dose (2-4 g)
Study: 24118830
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (Omacor®) low-dose (1 g)
Study: 24118830
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (Omacor®) low-dose + fluvastatin
Study: 24118830
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (Omacor®) high-dose + fluvastatin
Study: 24118830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no active drug)
Study: 17206633
Drug: Natalizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab (300 mg) plus infliximab (5 mg/kg)
Study: 16357613
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) alone
Study: 12476481
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% cream plus UVB radiation with penicillin
Study: 12476481
Drug: Betamethasone dipropionate
Normalized name: Betamethasone Dipropionate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone dipropionate 0.05% cream plus UVB radiation without penicillin
Study: 12476481
Drug: Oral psoralen
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral psoralen plus ultraviolet A (PUVA) therapy
Study: 12476481
Drug: Systemic retinoids
Normalized name: tocopheryl retinoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic retinoids therapy
Study: 1793881
Drug: midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.3 mg/kg
Study: 1793881
Drug: thiopental 5
Normalized name: thiopental 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: thiopental 5 mg/kg
Study: 1793881
Drug: diazepam 0.4
Normalized name: diazepam 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 0.4 mg/kg
Study: 6891235
Drug: Eucebral‐N (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eucebral‐N (80 mg etofylline and 100 mg cyclandelate) administered for 4 weeks
Study: 23219538
Drug: Epididymectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epididymectomy with concurrent administration of hyaluronic acid and carboxymethylcellulose (group 1)
Study: 18470667
Drug: Alendronate monotherapy
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate monotherapy (5 mg/day)
Study: 18470667
Drug: Vitamin K(2)
Normalized name: vitamin K 2
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K(2) (45 mg/day) plus alendronate (5 mg/day)
Study: 18470667
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamin K(2) and alendronate
Study: 1403077
Drug: Amoxicillin 50mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 50mg/kg/day in three divided doses for 10 days
Study: 3896885
Drug: nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine (30 mg/D)
Study: 31908254
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion until 2 h after surgery)
Study: 31908254
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with 0.9% saline (equal volume to lidocaine group)
Study: 28958701
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) influenza vaccine
Study: 28958701
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (SD) influenza vaccine
Study: 24708676
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care arm (two weekly hours of physical activity training for six weeks).
Study: 23218157
Drug: Adjunctive ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive ziprasidone 60-80 mg
Study: 23218157
Drug: Adjunctive ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive ziprasidone 20-40 mg
Study: 18573983
Drug: Fee per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fee per sealant treatment
Study: 15042614
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (60 mg)
Study: 11399692
Drug: Diagnosis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis of COPD after oral steroid trial
Study: 9240873
Drug: Iron-fortified formula
Normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-fortified formula (12.3 mg/l iron)
Study: 9240873
Drug: Non-fortified formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fortified formula (1.4 mg/l iron)
Study: 29946728
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg orally once daily for 21 days followed by 7 days off in 28-day cycles (n=278)
Study: 29946728
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg
Study: 20639271
Drug: IFNbeta‐1a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFNbeta‐1a treatment
Study: 17998225
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU intramuscular vitamin D2 injection
Study: 7808602
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Study: 7808602
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Study: 7808602
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tissue-type plasminogen activator (TD-2061), three times daily for 5 days
Study: 7808602
Drug: All dose
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dose groups (0.1 mg, 0.2 mg, 0.4 mg)
Study: 25865175
Drug: Frequent self-weighing
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Frequent self-weighing (daily or several times per week)
Study: 23332012
Drug: soluble vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: soluble vascular cell adhesion molecule (sVCAM)
Study: 23332012
Drug: tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: tumour necrosis factor-α receptor-I (TNFR-I)
Study: 17204967
Drug: Micronutrient sprinkles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient sprinkles (MMN) containing iron 12.5 mg + folic acid 150 microg + zinc 5 mg + vitamins A, C and D3
Study: 17204967
Drug: Iron/folate sprinkles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron/folate sprinkles (iron 12.5 mg + folic acid 150 microg)
Study: 15171476
Drug: deltaBV/UF ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: deltaBV/UF ratio of less than 2.6%/L
Study: 11369149
Drug: Self-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment group (n=123)
Study: 11369149
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (self-treatment and active control)
Study: 9260599
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg orally twice a day
Study: 9260599
Drug: Ondansetron suppository
Normalized name: ondansetron Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron suppository 16 mg once daily
Study: 23572341
Drug: 30% inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% inhaled xenon for 24 h combined with 72 h of moderate systemic hypothermia
Study: 19066383
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (monthly weigh-ins)
Study: 8893656
Drug: Benzodiazepine (mini
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine (mini doses)
Study: 6391442
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol hydrochloride 0.5% every 12 hours
Study: 6391442
Drug: Topical betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betaxolol hydrochloride 0.5% every 12 hours with oral acetazolamide 500 mg every 12 hours
Study: 6391442
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide 500 mg every 12 hours
Study: 6391442
Drug: Oral acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acetazolamide 500 mg every 12 hours with topical betaxolol
Study: 31733455
Drug: S-Adenosyl-Methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Adenosyl-Methionine (SAMe) 3,200 mg/day
Study: 23910908
Drug: Gastric acid
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric acid suppressive medications (AS)
Study: 21477068
Drug: Salbutamol (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (6 mg)
Study: 19678813
Drug: 5‐ASA‐MMX (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐ASA‐MMX (2.4 g/day, once daily)
Study: 19678813
Drug: Asacol (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol (2.4 g/day, twice daily)
Study: 17197641
Drug: Rofecoxib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (50 mg/day; NSAID)
Study: 2171595
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy (40 Gy in the chest tumour)
Study: 350496
Drug: Co-trimoxazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (6 mg trimethoprim plus 30 mg sulphamethoxazole/kg)
Study: 350496
Drug: Streptomycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin (50 mg/kg)
Study: 350496
Drug: Neomycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (50 mg/kg)
Study: 7036289
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (chemotherapy, immunotherapy, and chemoimmunotherapy)
Study: 22315328
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.25 ml s(‐1)
Study: 22315328
Drug: Ropivacaine 1
Normalized name: ROPivacaine 1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 1 ml kg(‐1) 0.2% or 0.35% at an injection speed of 0.5 ml s(‐1)
Study: 19822404
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium patch
Study: 19822404
Drug: Control (menthol)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (menthol) patch
Study: 17601378
Drug: ACEI/ATRA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ATRA therapy for 62+/−5 months
Study: 17601378
Drug: ACEI/ATRA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ATRA therapy for 62+/−5 months among patients with genotype II
Study: 17601378
Drug: ACEI/ATRA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ATRA therapy
Study: 11519502
Drug: Metronidazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (two 2-g doses, 48 hours apart, repeated at 24 to 29 weeks)
Study: 11519502
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two doses, 48 hours apart, repeated at 24 to 29 weeks)
Study: 9285463
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg/day) and levodopa
Study: 9285463
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of selegiline
Study: 8289134
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg daily oral doses
Study: 8289134
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg daily oral doses
Study: 8289134
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg daily oral doses
Study: 2951449
Drug: rHBsAg vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHBsAg vaccine (20 micrograms intramuscular dose)
Study: 2951449
Drug: HEPTAVAX-B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEPTAVAX-B vaccine (plasma-derived)
Study: 28294694
Drug: Intraoral Low-Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral Low-Level Laser Therapy (LLLT)
Study: 28294694
Drug: Transcutaneous Low-Level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous Low-Level Laser Therapy (LLLT)
Study: 27260639
Drug: Plaster cast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaster cast treatment (immobilisation in a below elbow cast for 6 to 10 weeks)
Study: 27260639
Drug: Immediate surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate surgical fixation (using preferred technique and implant)
Study: 27260639
Drug: Plaster cast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaster cast treatment
Study: 22100058
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day plus ezetimibe 10 mg/day
Study: 17956583
Drug: Cyclophosphamide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (single intravenous infusion)
Study: 17956583
Drug: Intratumoral bacille
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral bacille Calmette‐Guérin (BCG) immunotherapy
Study: 15899957
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion during hyperglycemic clamp (7 mm)
Study: 15899957
Drug: GIP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GIP infusion during hyperglycemic clamp (7 mm)
Study: 17223419
Drug: Postprocedural heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprocedural heparin (n = 758; median duration 2 days)
Study: 17223419
Drug: Postprocedural heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprocedural heparin (n = 758)
Study: 17223419
Drug: Postprocedural heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprocedural heparin (n = 555)
Study: 8592662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose studies of immediate release products
Study: 8592662
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose studies of immediate release products
Study: 8592662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose studies of sustained release products
Study: 8592662
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose studies of sustained release products
Study: 8592662
Drug: Multiple dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose studies
Study: 8592662
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose studies
Study: 1136854
Drug: Theophyllamine (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophyllamine (as the only active drug)
Study: 30907035
Drug: Neiguan point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neiguan point acupuncture combined with amiodarone therapy
Study: 30907035
Drug: Amiodarone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone therapy alone
Study: 18259856
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC: doxorubicin or epirubicin, plus cyclophosphamide) added to ovarian function suppression/ablation (OFS) and 5 years of tamoxifen
Study: 15875528
Drug: Ciclesonide 320
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclesonide 320 microg once daily
Study: 12765916
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 microg twice daily
Study: 15283939
Drug: Dydrogesterone (DYD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (DYD; 10 mg per day)
Study: 15283939
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA; 10 mg per day)
Study: 15283939
Drug: Nomegestrol acetate
Normalized name: nomegestrol acetate
DrugBank: Nomegestrol acetate (DB13981)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Nomegestrol acetate (NMG; 5 mg per day)
Study: 15283939
Drug: Norethisterone acetate
Normalized name: Norethisterone acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethisterone acetate (NETA; 10 mg per day)
Study: 11694700
Drug: Intramuscular benzathine
Normalized name: Cephapirin Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular benzathine penicillin G (BPG)
Study: 6869040
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (n = 12)
Study: 6869040
Drug: Small group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small group therapy (n = 11)
Study: 6869040
Drug: Large group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large group therapy (n = 11)
Study: 28728602
Drug: Enhanced upper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced upper limb therapy for 45 min, three times/week for 12 weeks
Study: 10403069
Drug: Rizatriptan 10-mg
Normalized name: rizatriptan 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 10-mg wafer
Study: 10403069
Drug: Rizatriptan 5-mg
Normalized name: rizatriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rizatriptan 5-mg wafer
Study: 8024907
Drug: 1% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% etidocaine 10 ml
Study: 8024907
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution 10 ml
Study: 798110
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (6 mg of stanozolol per day)
Study: 28394217
Drug: Control Exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Exposure Therapy (CET)
Study: 23517508
Drug: Nadroparin 2850
Normalized name: Nadroparine
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 2850 IU/0.3 ml subcutaneously once a day for 12 months
Study: 23517508
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment alone (control group)